1097: High Sensitivity and Specificity of the High Molecular Isoform of Tenascin-C to Detect Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 289-289
Author(s):  
Heiko Wunderlich ◽  
Kathrin Katenkamp ◽  
Alexander Berndt ◽  
Jörg Schubert ◽  
Hartwig Kosmehl
2020 ◽  
Author(s):  
Alireza Emamvirdizadeh ◽  
Faranak Jamshidian ◽  
Mehrdad Hashemi ◽  
Saghi Nooraei ◽  
Maliheh Entezari

Abstract Background: Prostate cancer is the most prevalent cancer among men worldwide. Diagnosis in this cancer is primarily done using aggressive methods, such as biopsy. Laboratory methods, such as measurement of prostate specific antigen (PSA) in the blood, do not have high sensitivity and specificity. MicroRNAs, a group of diagnostic biomarkers, can be used to diagnose diseases such as cancer. MicroRNA is small, non-coding, single-stranded RNA with a length of 21-23 nucleotides. The present study was undertaken to investigate changes in the expression level of miR-21 and miR-214 in the urine to detect prostate cancer. Methods: Testing was done on 70 urine samples from prostate cancer patients (32 metastatic and 38 non-metastatic) and 30 from healthy individuals with negative biopsy reports as the control group. Changes in the expression level of miR-21 and miR-214 in the urine were investigated by using qRT-PCR. Results: miR-21 showed a significant increase in expression (p = 0.003) and miR-214 showed a significant decrease in expression (p = 0.000) over the results of the control group. The specificity, sensitivity and AUC for combined panels of both microRNAs were 100%, 72.14% and 0.721 and for PSA were 63.33%, 61.43% and 0.620, respectively. Conclusions: The results show that miR-21 and miR-214 show significant changes in expression in patients with prostate cancer compared to the control group. A combined panel of miR-21 and miR-214 can be used as a non-invasive method for detecting prostate cancer with higher sensitivity and specificity than the PSA test.


2007 ◽  
Vol 23 (1-2) ◽  
pp. 31-41 ◽  
Author(s):  
Vera L. Costa ◽  
Rui Henrique ◽  
Carmen Jerónimo

Prostate cancer is a highly prevalent malignancy, which is clinically silent but curable while organ-confined. Because available screening methods show poor sensitivity and specificity, the development of new molecular markers is warranted. Epigenetic alterations, mainly promoter hypermethylation of cancer-related genes, are common events in prostate cancer and might be used as cancer biomarkers. Moreover, the development of quantitative, high-throughput techniques to assess promoter methylation enabled the simultaneous screening of multiple clinical samples. From the numerous cancer-related genes hypermethylated in prostate cancer only a few proved to be strong candidates to become routine biomarkers. This small set of genes includesGSTP1,APC,RARβ2,Cyclin D2,MDR1, andPTGS2. Single and/or multigene analyses demonstrated the feasibility of detecting early prostate cancer, with high sensitivity and specificity, in body fluids (serum, plasma, urine, and ejaculates) and tissue samples. In addition, quantitative hypermethylation of several genes has been associated with clinicopathologic features of tumor aggressiveness, and also reported as independent prognostic factor for relapse. The identification of age-related methylation at specific loci and the differential frequency of methylation among ethnical groups, also provided interesting data linking methylation and prostate cancer risk. Although large trials are needed to validate these findings, the clinical use of these markers might be envisaged for the near future.


Author(s):  
Yahui Peng ◽  
Yulei Jiang ◽  
Ximing J. Yang

Immunohistochemistry (IHC) is an adjunct tool for clinical histologic diagnosis of diseases. A common IHC technique for prostate cancer diagnosis is a triple-antibody cocktail with Alpha-Methylacyl-CoA Racemase (AMACR), p63, and High-Molecular-Weight Cytokeratin (HMWCK), which stains certain types of cells into two distinct colors. The authors have developed an automated computer technique that detects prostate cancer in prostate tissue sections processed with the triple-antibody cocktail. Test and validation of the authors’ technique on digital images obtained from conventional microscopes (region of interest images) showed that the computer technique can recognize prostatic adenocarcinoma with both high sensitivity and high specificity. The authors also used this computer technique to analyze whole-slide images of prostate biopsy and the initial results are promising. With further development and refinement, this computer technique could become a useful tool for pathologists to detect prostate cancer foci in histologic sections of tissue processed with the triple-antibody cocktail.


Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1029
Author(s):  
Rania Makboul ◽  
Islam F. Abdelkawi ◽  
Dalia M. Badary ◽  
Mahmoud R. A. Hussein ◽  
Johng S. Rhim ◽  
...  

The histopathologic diagnosis of prostate cancer (PCa) from biopsies is a current challenge if double or triple staining is needed. Therefore, there is an urgent need for development of a new reliable biomarker to diagnose PCa patients. We aimed to explore and compare the expression of TMTC4 in PCa cells and tissue specimens and evaluate its sensitivity and specificity. The expression of TMTC4 in PCa and normal prostate epithelial cells was determined by real-time PCR and Western blot analyses. Immunohistochemical (IHC) staining of TMTC4 was performed on tissues collected from PCa and benign prostatic hyperplasia (BPH). Our results show a high expression of TMTC4 on mRNA and protein levels in PCa versus BPH1 and normal cells (p < 0.05). IHC results show strong cytoplasmic expressions in PCa cases (p < 0.001) as compared to BPH cases. The overall accuracy as measured by the AUC was 1.0 (p < 0.001). The sensitivity and specificity of the protein were 100% and 96.6%, respectively. Taken together, we report a high TMTC4 expression in PCa cells and tissues and its ability to differentiate between PCa and BPH with high sensitivity and specificity. This finding can be carried over to clinical practice after its confirmation by further studies.


2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Alireza Emamvirdizadeh ◽  
Faranak Jamshidian ◽  
Maliheh Entezari ◽  
Saghi Nooraei ◽  
Mehrdad Hashemi

Background: Prostate cancer is the most prevalent cancer among men worldwide. Diagnosis in this cancer is primarily done, using aggressive methods such as biopsy. Laboratory methods, such as the measurement of prostate-specific antigen (PSA) in the blood, do not have high sensitivity and specificity. MicroRNAs (miRNAs), a group of diagnostic biomarkers, can diagnose diseases such as cancer. MicroRNA (miRNA) is a small, non-coding, single-stranded RNA with a length of 21 to 23 nucleotides. Objectives: This study was designed to investigate the changes in the expression level of miR-21 and miR-214 in the urine of patients with prostate cancer compared with healthy controls. Methods: A total of 70 urine samples from prostate cancer patients (32 metastatic and 38 non-metastatic) and 30 from healthy subjects with negative biopsy reports were collected. The expression level of miR-21 and miR-214 in the urine were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results: miR-21 showed a significant increase in expression (P = 0.003) and miR-214 showed a significant decrease in expression (P = 0.000) compared with the control group. The specificity, sensitivity, and area under the curve (AUC) were 100, 72.14, and 0.721% for combined panels of miR-21 and miR-214 and 63.33, 61.43, and 0.620%, respectively, for PSA. Conclusions: miR-21 and miR-214 showed significant change in expression in patients with prostate cancer compared with healthy subjects. It is hoped that, with further research, a combined panel of miR-21 and miR-214 can be used as a non-invasive method for detecting prostate cancer with higher sensitivity and specificity than the PSA test.


2010 ◽  
Vol 48 (08) ◽  
Author(s):  
A Rosenthal ◽  
H Köppen ◽  
R Musikowski ◽  
R Schwanitz ◽  
J Behrendt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document